Literature DB >> 3319462

Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas.

M S McPhee1, J T Swan, W L Biddle, N J Greenberger.   

Abstract

We report results of a prospective study of daily 5-ASA enema therapy in patients with proctocolitis that was unresponsive to conventional therapy. Forty-seven patients with active colonic inflammation distal to the splenic flexure have been followed for three months to three years. Rapid improvement was noted within three months in 41 of 47 (87%) patients, while six failed therapy. Of the 41 patients responding to therapy, 39 achieved complete remission. Nineteen patients have relapsed at least once following discontinuation of 5-ASA, but 23 of 25 (92%) relapse episodes responded to a course of 5-ASA therapy. Complications of 5-ASA therapy were limited to hemorrhoidal irritation and local perianal injury. We conclude that 5-ASA enema is effective in inducing remission in patients with proctocolitis unresponsive to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319462     DOI: 10.1007/BF01312469

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Observations on idiopathic proctitis.

Authors:  J E LENNARD-JONES; G W COOPER; A C NEWELL; C W WILSON; F A JONES
Journal:  Gut       Date:  1962-09       Impact factor: 23.059

2.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

3.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

4.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

5.  Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.

Authors:  K M Das; J R Chowdhury; B Zapp; J W Fara
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

6.  Nephrotoxic lesions from 5-aminosalicylic Acid.

Authors:  I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Br Med J       Date:  1972-01-15

7.  Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.

Authors:  A Shafii; J R Chowdhury; K M Das
Journal:  Am J Gastroenterol       Date:  1982-05       Impact factor: 10.864

8.  Retrograde spreading of hydrocortisone enema in inflammatory bowel disease.

Authors:  M Jay; G A Digenis; T S Foster; D R Antonow
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

9.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

10.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

View more
  5 in total

Review 1.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 2.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

3.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 4.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 5.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.